The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
A Rosso, E Pitini, E D'Andrea...
https://pubmed.ncbi.nlm.nih.gov/28715059Actively Recruiting
Led by Odense University Hospital · Updated on 2026-02-20
2000
Participants Needed
2
Research Sites
N/A
Total Duration
Familial hypercholesterolemia (FH) is a common inherited disorder affecting lipid metabolism, yet it remains largely underdiagnosed, with only about 15% of an estimated 30,000 patients identified in Denmark. This study aims to evaluate whether adding a biochemistry interpretive comment on elevated LDL cholesterol levels can increase referrals to lipid clinics and improve the detection rate of FH. The study uses a step wedge cluster randomized controlled trial design across the Region of Southern Denmark to test this approach. The intervention involves implementing an interpretive comment on LDL-C levels that encourages healthcare providers to investigate secondary causes of dyslipidemia and refer patients to lipid clinics when FH is suspected. This comment will be introduced stepwise in four clusters of general practitioners and hospital wards based on their laboratory providers. The LDL-C thresholds for triggering the comment are 4 mmol/L for people under 40 years old and 5 mmol/L for those 40 or older. The intervention period lasts 52 weeks with clusters adopting the comment at 12-week intervals. Participants are patients referred to lipid clinics in Southern Denmark with elevated LDL-C levels meeting the study criteria. Researchers will collect data from electronic patient records to measure the number of referrals and confirmed FH diagnoses, along with laboratory values like HbA1c, TSH, and lipid profiles. Outcomes include changes in LDL-C from referral to first clinic contact and the rate of new FH diagnoses. The study will also assess how many referrals are needed to identify one FH patient, with a total duration of 52 weeks including buffer periods.
CONDITIONS
Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Participants referred to lipid clinics of Southern Denmark are assessed based on LDL cholesterol levels and other health criteria.
Duration - Up to 52 weeks
Participants who have elevated LDL cholesterol levels receive a biochemistry interpretive comment encouraging further investigation for secondary dyslipidemia and referral to lipid clinics if needed.
Referral data and patient outcomes are monitored through electronic patient journal systems over the study period.
Duration - 3 to 12 months
Participants referred to lipid clinics are followed up to assess changes in LDL cholesterol and confirm diagnosis of familial hypercholesterolemia through clinical scoring and genetic testing.
Participants may have visits at lipid clinics for blood tests and clinical evaluation, including genetic testing results over 9 to 12 months.
Total: 2 locations
1
Odense University Hospital
Odense, Funen, Denmark, 5000
Actively Recruiting
2
Departement of Cardiology, Odense University Hospital
Odense C, Denmark, 5000
Actively Recruiting
J
Jakob Knold, MD
F
Finn Lund Henriksen, Ph.d.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
SCREENING
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
A Rosso, E Pitini, E D'Andrea...
https://pubmed.ncbi.nlm.nih.gov/28715059Amy C Sturm, Joshua W Knowles, Samuel S Gidding...
https://pubmed.ncbi.nlm.nih.gov/30071997Frederick J Raal, G Kees Hovingh, Alberico L Catapano
https://pubmed.ncbi.nlm.nih.gov/30270089Erik Berg Schmidt, Berit Storgaard Hedegaard, Kjetil Retterstøl
https://pubmed.ncbi.nlm.nih.gov/32933999Ian M Barlow
https://pubmed.ncbi.nlm.nih.gov/18275680K Hemming, T P Haines, P J Chilton...
https://pubmed.ncbi.nlm.nih.gov/25662947